August 9, 2025Journal of Clinical MedicineOpen Access

Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design

View Full Paper

Ask AI

Bookmark

Calcitonin remains the cornerstone biomarker for medullary thyroid carcinoma, crucial for diagnosis and surveillance.
Procalcitonin is emerging as a stable alternative to calcitonin, particularly when levels are indeterminate, while carcinoembryonic antigen is useful for assessing disease aggressiveness.
Kinetic evaluation of calcitonin and carcinoembryonic antigen offers significant prognostic information, where doubling times of less than 6 months correlate with poor survival.
The proposed framework integrates both established and emerging biomarkers for better diagnostic precision and personalizes treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Narrative review explores circulating biomarkers for medullary thyroid carcinoma, suggesting an evidence-based algorithm for enhanced clinical decision-making.

Cite This Study

Giovanella et al. (2025) studied this question.

synapsesocial.com/papers/68af2695cf1dd9ea359e228e https://doi.org/10.3390/jcm14165645

View Full Paper

Ask AI

Bookmark

Implication

Narrative review explores circulating biomarkers for medullary thyroid carcinoma, suggesting an evidence-based algorithm for enhanced clinical decision-making.

Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design

Key Points

Discussion

Implication

Cite This Study

Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider